ISONIAZID; PYRAZINAMIDE; RIFAMPIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for isoniazid; pyrazinamide; rifampin and what is the scope of freedom to operate?
Isoniazid; pyrazinamide; rifampin
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for ISONIAZID; PYRAZINAMIDE; RIFAMPIN
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 38 |
| DailyMed Link: | ISONIAZID; PYRAZINAMIDE; RIFAMPIN at DailyMed |
Recent Clinical Trials for ISONIAZID; PYRAZINAMIDE; RIFAMPIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centers for Disease Control and Prevention | Phase 2/Phase 3 |
| Tuberculosis Trials Consortium | Phase 2/Phase 3 |
| First Affiliated Hospital of Zhejiang University | Phase 3 |
US Patents and Regulatory Information for ISONIAZID; PYRAZINAMIDE; RIFAMPIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | RIFATER | isoniazid; pyrazinamide; rifampin | TABLET;ORAL | 050705-001 | May 31, 1994 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
